OrbiMed Capital GP IX LLC — SEC Form 4 filings
SEC reporting owner CIK 1920574. 5 Form 4 filings on record with FilingPulse; latest filed 2026-08-11.
Transaction summary — filings shown
Covers all 5 filings on record, filed 2024-11-05 to 2026-08-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 2 filings — 8,246,127 shares, $40,391,826 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: purchase of 1,666,667 shares @ $18.00 ($30,000,006) in Braveheart Bio, Inc., filed 2026-08-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | Director, 10% owner | 1 | 2 legs · 1,940,000 sh · $34,920,000 | — | 2 |
| Shattuck Labs, Inc. (STTK) | Director | 3 | 2 legs · 6,306,127 sh · $5,471,826 | — | 10 |
| Lomond Therapeutics Holdings, Inc. | Director | 1 | — | — | 13 |
Form 4 filings — OrbiMed Capital GP IX LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-11 | 4 | Braveheart Bio, Inc. (BRVE) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Conversion (C): 9,132,420 · Purchase (P): 1,666,667 @ $18 · Purchase (P): 273,333 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Shattuck Labs, Inc. (STTK) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Purchase (P): 1,041,667 (derivative) · Purchase (P): 208,333 (derivative) | EDGAR |
| 2026-06-09 | 4 | Shattuck Labs, Inc. (STTK) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Conversion (C): 15,366,490 (derivative) · Conversion (C): 3,073,298 (derivative) · Conversion (C): 15,366,490 (derivative) · Conversion (C): 3,073,298 (derivative) | EDGAR |
| 2025-09-02 | 4 | Shattuck Labs, Inc. (STTK) jointly with ORBIMED ADVISORS LLC, OrbiMed Genesis GP LLC | Purchase (P): 5,255,106 @ $0.87 · Purchase (P): 1,051,021 @ $0.87 · Purchase (P): 10,111,384 (derivative) · Purchase (P): 2,022,277 (derivative) · Purchase (P): 15,366,490 (derivative) · Purchase (P): 3,073,298 (derivative) | EDGAR |
| 2024-11-05 | 4 | Lomond Therapeutics Holdings, Inc. jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Capital GP VIII LLC | Conversion (C): 323,916 @ $3.20 · Conversion (C): 215,146 @ $3.20 · Conversion (C): 389,078 @ $3.60 · Conversion (C): 230,753 @ $3.60 · Conversion (C): 74,613 @ $3.60 · Grant/award (A): 808,894 @ $4 · +7 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1920574 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →